A Dixon, Illinois man, Gary Davey, diagnosed with metastatic prostate cancer nearly 14 years ago, has experienced a remarkable turnaround through clinical trials at UW Health Carbone Cancer Center in Madison. His cancer, once widespread, is now undetectable, offering hope and extending his life expectancy.
Davey's journey began with a routine blood test that revealed the initial prostate cancer diagnosis. Despite undergoing prostate removal, the cancer returned a year later, progressing to metastatic prostate cancer. Facing a grim prognosis, Davey opted for clinical trials at UW Health Carbone Cancer Center, led by Dr. Joshua Lang, instead of chemotherapy. One trial involved taking multiple pills daily.
"We're writing medical history because no one has lived this long," Davey said, highlighting the unprecedented success of his treatment.
The specific trial Davey participated in utilizes a newer class of drugs that has since gained FDA approval and is available worldwide. Dr. Lang emphasized the broader impact of Davey's participation, stating, "Because of what he has done... hundreds, thousands of men now have access to treatment because of the clinical trial Gary was part of."
Metastatic prostate cancer is generally considered incurable, but Davey's case demonstrates the potential of clinical trials and novel therapies to significantly extend life and improve quality of life. While his cancer is currently undetectable, he continues treatment and regular check-ups with Dr. Lang. He also advocates for regular PSA testing for early detection.
"My life's pretty much perfect. Which is a strange thing to say when you've got terminal, not terminal anymore; when you've got cancer. It's perfect," Davey said.
